Clinical Trial Site

Jacksonville, Florida 32258

4 studies enrolling now · 15 studies all time

What they study most

ALA Dehydratase Deficient Porphyria (ADP), ATTR Amyloidosis, Acute Hepatic Porphyria, Acute Intermittent Porphyria (AIP), Advanced Hepatocellular Carcinoma, Amyloidosis, Amyloidosis, Hereditary, Cerebral Amyloid Angiopathy, Dermatomyositis, Generalized Myasthenia Gravis, Hepatic Porphyrias, Hereditary Coproporphyria (HCP)

Studies at this site

• A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma — Recruiting now
• ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) — Recruiting now
• Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) — Recruiting now
• A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis — Running, not enrolling
• NE3107 in Adults With Neurological Symptoms of Long COVID — Running, not enrolling
• Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) — Completed
• HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) — Completed
• A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension — Completed
• Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) — Completed
• A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1 — Completed
• The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) — Completed
• A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation — Completed
• INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP — Stopped early